PembrolizumabInterstitial lung disease: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1778卷 / 1期

关键词：

D O I：

10.1007/s40278-019-71173-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：370 / 370

相关论文

共 50 条

[31] AlectinibInterstitial lung disease: case report
Reactions Weekly, 2017, 1655 (1) : 16 - 16
[32] OsimertinibInterstitial lung disease: case report
Reactions Weekly, 2018, 1700 (1) : 200 - 200
[33] CetuximabInterstitial lung disease: case report
Reactions Weekly, 2017, 1651 (1) : 75 - 75
[34] NivolumabInterstitial lung disease: case report
Reactions Weekly, 2021, 1846 (1) : 242 - 242
[35] IxekizumabInterstitial lung disease: case report
Reactions Weekly, 2024, 2039 (1) : 285 - 285
[36] NivolumabInterstitial lung disease: case report
Reactions Weekly, 2018, 1712 (1) : 398 - 398
[37] GefitinibInterstitial lung disease: case report
Reactions Weekly, 2013, 1450 (1) : 18 - 18
[38] RituximabInterstitial lung disease: case report
Reactions Weekly, 2016, 1617 (1) : 196 - 196
[39] CrizotinibInterstitial lung disease: case report
Reactions Weekly, 2016, 1597 (1) : 70 - 70
[40] TozinameranInterstitial lung disease: case report
Reactions Weekly, 2021, 1886 (1) : 377 - 377

← 1 2 3 4 5 →